<DOC>
	<DOCNO>NCT00364026</DOCNO>
	<brief_summary>This research study new experimental drug call darusentan . Darusentan currently approve U.S. Food Drug Administration ( FDA ) use United States , mean doctor prescribe drug . The purpose study determine darusentan effective reduce systolic blood pressure subject resistant systolic hypertension , despite treatment full dos three blood pressure lower drug , include diuretic .</brief_summary>
	<brief_title>A Clinical Study Evaluate Effects Darusentan Safety Efficacy Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three More Blood Pressure Lowering Drugs</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>LU 135252</mesh_term>
	<criteria>Subjects competent provide write consent Aged 35 85 year Subjects diabetes and/or chronic kidney disease must mean systolic blood pressure ≥130 mmHg All subject must mean systolic blood pressure ≥140 mmHg Receiving adhere full dos appropriate guidelinerecommended antihypertensive drug three different class antihypertensive agent , include diuretic Female subject childbearing potential must negative serum pregnancy test Screening Visit negative urine pregnancy test time Randomization . Average sit systolic blood pressure ≥180 mmHg diastolic blood pressure ≥110 mmHg Screening Serum ALT AST &gt; 2X ULN Subjects experience myocardial infarction , unstable angina , cerebrovascular accident ( CVA ) within 6 month Screening Visit ; sick sinus syndrome second third degree atrioventricular block , chronic atrial fibrillation recurrent atrial tachyarrhythmia , recurrent ventricular tachycardia , symptomatic bradycardia Implanted cardioverter defibrillator ( ICD ) fire arrhythmia within 3 month Screening implanted pacemaker Symptomatic CHF require treatment Hemodynamically significant valvular heart disease Hemodialysis peritoneal dialysis ; history renal transplant Diagnosis recurrence malignancy within past 3 year Sleep apnea Subjects perform alternate shift night work Subjects participate clinical study involve another investigational drug device within 1 month Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2006</verification_date>
</DOC>